

## Certificate

The company apoplex medical technologies GmbH, founded in 2004 in Pirmasens, specializes in innovative medical technology solutions for stroke prevention worldwide. Its stroke risk analysis system is the first practical screening method that not only reliably detects episodes of atrial fibrillation, but also identifies the risk of paroxysmal atrial fibrillation in ECGs—even in the absence of active fibrillation episodes.

Ms. Chiara Schwarz-Weichhart was employed by apoplex medical technologies GmbH from August 2024 until 31 January 2026. From August 2024 to June 2025, she held the position of Product Manager and subsequently worked as a Product Owner until the end of her employment.

Due to her very good performance, her probationary period was successfully completed ahead of schedule after four months.

In her roles, Ms. Schwarz-Weichhart was responsible for the planning, coordination, and further development of our medical device products, working closely with internal departments as well as external stakeholders.

Her responsibilities included, in particular:

- Developing, maintaining, and communicating product roadmaps for the R&D organization in close collaboration with internal stakeholders
- Discussing and elaborating product ideas together with physicians, taking clinical requirements into account
- Translating clinical and stakeholder input into structured product concepts and wireframes
- Deriving, documenting, and maintaining stakeholder and system requirements from a market and customer perspective
- Creating and maintaining system requirements specifications
- Establishing and managing the software development ticketing system using ClickUp, including sprint planning, backlog management, workflow definition, and prioritization of requirements and bug fixes
- Planning, coordinating, and supporting product development activities in close cooperation with engineering teams
- Preparing and conducting sprint reviews with internal stakeholders
- Introducing and facilitating agile retrospectives within the development team
- Planning and coordinating product releases
- Validating implemented requirements and functionalities to ensure alignment with defined specifications
- Designing usability questionnaires and conducting surveys

- Independently planning, conducting, and evaluating usability tests
- Analyzing qualitative and quantitative usability data to support regulatory activities in accordance with the MDR
- Supporting product lifecycle activities, including post-market surveillance tasks
- Contributing to regulatory strategy development for new products
- Organizing and delivering internal product training sessions

Ms. Schwarz-Weichhart has very sound professional knowledge, which she applied reliably and effectively in practice. She worked in a structured, independent, and conscientious manner and demonstrated a high degree of responsibility. New tasks and requirements were quickly understood and implemented efficiently.

Her work results consistently met our expectations to a very high degree. Even under time pressure, she completed her tasks carefully and reliably. Her contributions, particularly in the areas of requirements management, usability engineering, agile process setup, and coordination between stakeholders, were consistently valuable to the product development process.

Her conduct toward supervisors, colleagues, and external partners was always professional, cooperative, and appropriate. She was a reliable and respected member of the team and contributed positively to a constructive working environment.

Ms. Schwarz-Weichhart is leaving our company on 31 January 2026. We thank her for her very good performance and wish her continued success and all the best for her professional and personal future. We would welcome the opportunity to work with her again in the future.

Pirmasens, 31.01.2026



Tobias Inderwies  
CEO apoplex medical technologies GmbH